SNSS - サネシス・ファ―マス―ティカルズ (Sunesis Pharmaceuticals Inc.)

SNSSのニュース

   Is Sunesis Pharmaceuticals (SNSS) Outperforming Other Medical Stocks This Year?  2020/03/17 15:30:10 Zacks Investment Research
Is (SNSS) Outperforming Other Medical Stocks This Year?
   Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q4 2019 Results - Earnings Call Transcript  2020/03/10 23:38:39 Seeking Alpha
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Q4 2019 Results Earnings Conference Call March 10, 2020, 4:30 pm ET Company Participants Willie Quinn - Chief Financ
   Sunesis Pharmaceuticals (NASDAQ:SNSS) Lifted to “Buy” at Zacks Investment Research  2019/11/16 16:24:33 Modern Readers
Sunesis Pharmaceuticals (NASDAQ:SNSS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday, Zacks.com reports. The brokerage currently has a $0.50 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 35.14% […]
   Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Short Interest Update  2019/11/14 14:15:40 Modern Readers
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 1,130,000 shares, a growth of 408.3% from the September 30th total of 222,300 shares. Approximately 1.8% of the shares of the company are sold short. Based on an average trading […]
   Sunesis Pharmaceuticals (NASDAQ:SNSS) Issues Earnings Results, Beats Estimates By $0.04 EPS  2019/11/14 03:58:44 Modern Readers
Sunesis Pharmaceuticals (NASDAQ:SNSS) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04, Fidelity Earnings reports. Shares of NASDAQ:SNSS traded down $0.05 during trading on Wednesday, reaching $0.42. 1,554,400 shares of the company traded hands, compared to its average volume of […]
   Sunesis Pharmaceuticals (NASDAQ:SNSS) Lifted to “Buy” at Zacks Investment Research  2019/11/16 16:24:33 Modern Readers
Sunesis Pharmaceuticals (NASDAQ:SNSS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday, Zacks.com reports. The brokerage currently has a $0.50 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 35.14% […]
   Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Short Interest Update  2019/11/14 14:15:40 Modern Readers
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 1,130,000 shares, a growth of 408.3% from the September 30th total of 222,300 shares. Approximately 1.8% of the shares of the company are sold short. Based on an average trading […]
   Sunesis Pharmaceuticals (NASDAQ:SNSS) Issues Earnings Results, Beats Estimates By $0.04 EPS  2019/11/14 03:58:44 Modern Readers
Sunesis Pharmaceuticals (NASDAQ:SNSS) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04, Fidelity Earnings reports. Shares of NASDAQ:SNSS traded down $0.05 during trading on Wednesday, reaching $0.42. 1,554,400 shares of the company traded hands, compared to its average volume of […]
   Sunesis Pharmaceuticals, Inc. (SNSS) Shares March Higher, Can It Continue?  2019/09/05 14:38:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals, Inc. (SNSS).
   Sunesis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?  2019/08/09 11:20:00 Zacks Investment Research
Sunesis Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
   Sunesis Pharmaceuticals (NASDAQ:SNSS) Lifted to “Buy” at Zacks Investment Research  2019/11/16 16:24:33 Modern Readers
Sunesis Pharmaceuticals (NASDAQ:SNSS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday, Zacks.com reports. The brokerage currently has a $0.50 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 35.14% […]
   Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Short Interest Update  2019/11/14 14:15:40 Modern Readers
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 1,130,000 shares, a growth of 408.3% from the September 30th total of 222,300 shares. Approximately 1.8% of the shares of the company are sold short. Based on an average trading […]
   Sunesis Pharmaceuticals (NASDAQ:SNSS) Issues Earnings Results, Beats Estimates By $0.04 EPS  2019/11/14 03:58:44 Modern Readers
Sunesis Pharmaceuticals (NASDAQ:SNSS) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04, Fidelity Earnings reports. Shares of NASDAQ:SNSS traded down $0.05 during trading on Wednesday, reaching $0.42. 1,554,400 shares of the company traded hands, compared to its average volume of […]
   Sunesis Pharmaceuticals, Inc. (SNSS) Shares March Higher, Can It Continue?  2019/09/05 14:38:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals, Inc. (SNSS).
   Sunesis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?  2019/08/09 11:20:00 Zacks Investment Research
Sunesis Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

calendar